Excerpt from the book "Increasing IQ, Cognition and COVID-19 Cure Rate with Essential Nutrients ..... Targeted Detox Improves Children’s IQ, ADHD Behavior, and Adult Cognition by Dennis N Crouse
Chapter 11. Crouse Protocol for Reversing MCI and AD
Efficacy of Cholinesterase Inhibitors and Memantine
Many people with mild cognitive impairment (MCI) and
mild Alzheimer’s disease (AD) are prescribed a cholinesterase inhibitor (ChEI). Those with moderate to severe AD (e.g., Mini-Mental
State Examination [MMSE] scores below 15) are prescribed memantine, with in
some cases a ChEI. Administration of a ChEI increases the
concentration of acetylcholine by inhibiting its breakdown. These drugs treat some
of the symptoms of MCI, such as memory loss, agitation, apathy, and psychotic
symptoms including delusions, hallucinations, and disordered thought. Examples
of ChEIs are:
·
Galantamine (trade name Razadyne) is approved by
the FDA for treatment of vascular dementia and mild to moderate AD. It enhances
memory in brain-damaged adults544.
·
Rivastigmine (trade name Excelon) is approved to for mild and moderate
AD.
·
Donepezil (trade name Aricept) is approved to treat all stages of
AD.
A study was published in 2011 on the efficacy
of these three ChEIs and memantine taken by patients diagnosed with MCI or mild
AD. Approximately one-half of 392 MCI patients and two-thirds of 188 mild AD
patients were APOE-4 carriers. Among the MCI
patients 33.4% received only ChEIs, 11.7% received ChEIs and memantine, and 54.9%
received neither. Among the 188 AD patients 38.9% received ChEIs, 45.7% ChEIs
and memantine, and 15.4% neither817.
The patients with MCI were divided into three
groups, only 22% of the non-treated group progressed to dementia, 43% of the
ChEI treated group progressed to dementia, and 56% of the group treated with
both memantine and ChEI progressed to dementia. Therefore, there is a greater risk of dementia among people taking these
drugs. The mean time to dementia was 30% quicker in the ChEI treated group than
the untreated group and 42% quicker for the memantine and ChEI treated group
than the untreated group. Both MCI patients and AD patients who received ChEI
treatment had a more severe decline in cognition than untreated patients. Therefore,
these drugs may reduce symptomology of MCI and AD but both increase the risk of
dementia and hasten the progression to dementia when compared with un-treated
people817.
I have an acquaintance with MCI who was
prescribed Aricept to improve her short-term memory but had trouble sleeping
once she began taking the drug. The doctor then recommended a sleeping pill
with the side effect of memory impairment. This is an example of a doctor being
uniformed on the negative side effects of a prescribed drug.
